IMROZ Clinical Trial Sentiment
Total Impressions 200,306
Sentiment Analysis
| Doctor Name |
Sentiment |
Comment |
|
Ben Derman |
POSITIVE
|
PFS clearly in favor of Isa-VRd. Median f/u 60 months VRd arm did better than historical comps. Isa-VRd with 5-year PFS of 63%. This compares favorably with MAIA with Dara-Rd (~50%) and less than PERSEUS with Dara-VRd/ASCT (4-yr PFS 83%). Benefit consistent across subgroups. https://t.co/4Ghbzp41yk |
|
Dr. SUNDARARAJAN RAJKUMAR |
POSITIVE
|
The 5 year PFS of 62% is impressive and this trial along with one other similar phase III at #ASCO24 is providing new data on quads in elderly. With dose adjustment and monitoring this approach is feasible in patients who are transplant ineligible but not frail. |
| Sara Fagerlie, PhD, CHCP (she/her) |
POSITIVE
|
Great discussion by @DrOlaLandgren at #ASCO24 of IMROZ, BENEFIT, & PERSEUS. Quads=higher rates of MRD and longer PFS vs triplets, regardless of age and ASCT eligibility. New SOC in #NDMM. Time to retire transplant eligible and ineligible terminology? @hemeoncnews @OncoAlert #mmsm https://t.co/YopUBUleQa |
|
Muzaffar Qazilbash |
POSITIVE
|
#ASCO24 IMROZ trial. Isa-VRd vs. VRd in transplant-ineligible NDMM. N=446, ~97% patients 65-80 years with ECOG PS 0-1; 5-year PFS 63% vs. 45% favoring Isa-VRd. No unexpected toxicities #mmsm @NEJM @thanosdimop @Myeloma_Doc @mbeksac56 https://t.co/5FGxhbYJWl |
|
Dr. SAMER AL HADIDI |
NEUTRAL
|
#mmsm #ASCO24 1ļøā£ IMROZ: Isa-VRd vs VRd i n transplant-ineligible NDMM pts ā”ļø https://t.co/BLS3sPJZ1F ā
follow-up: 5 years ā
Median PFS Isa-VRd(NR, estimated 7.5 years!!) vs VRd(4.5 years) š Grade 5 TEAE: 2 times higher with Isa-VRd (11% vs 5.5%) https://t.co/08UepenQIc |
|
Dr. SUNDARARAJAN RAJKUMAR |
NEUTRAL
|
1) The Triplet vs Quad trials with will define role of quads in elderly patients with newly diagnosed myeloma. They also provide frontline phase III data with Isatuximabā and a choice between Dara and Isa. For some patients Isa will be more cost effective. @Myeloma_Doc #ASCO24 |
|
Dr. SAMER AL HADIDI |
NEUTRAL
|
#mmsm #ASCO24 Thoughts on IMROZ Very important data ā
median PFS: 7.5 yrs(estimated) ā
Grade IV AEs: higher though compare to: MAIA: Dara-Rd: median F/U <5yrs (shorter median follow up),death related to AEs (10%) in Dara-Rdš https://t.co/P9cra0bSzv |
|
Mike Thompson, MD, PhD, FASCO |
NEUTRAL
|
IMROZ VRd +/- Isa #mmsm #ASCO24 Summary - Facon https://t.co/zJBz2gdUSP |
|
Dr. SUNDARARAJAN RAJKUMAR |
NEUTRAL
|
Third of the @NEJM #ASCO24 myeloma papers Iām highlighting. The IMROZ trial exploring quadrupletx, Isa-VRd, in transplant ineligible patients with newly diagnosed myeloma. @thanosdimop @Myeloma_Doc #ThierryFacon @Mohty_EBMT @TomBmt133 https://t.co/yTpeFvXyHs |
|
Ben Derman |
NEUTRAL
|
IMROZ data is out in @NEJM simultaneous with oral pres. As for treatment schedule, these were 6 week cycles with reduced dose dex and twice weekly bortezomib. Mostly std risk patients were enrolled but 36% had 1q gain. Median age 72 (26% >=75) https://t.co/OyMl51vQgH #ASCO24 https://t.co/aVh6K7xDvB |
| Ghazi Alotaibi |
NEGATIVE
|
@ManniMD1 Also that dex schedule and velcade twice a week protocol is anything but tolerable. |